Ann Lee's Insider Trades & SAST Disclosures
Ann Lee's most recent trade in Prime Medicine Inc was a trade of 275,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 27, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Ann Lee.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Prime Medicine Inc | Ann L. Lee | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 275,000 | 275,000 | - | - | Stock Option (right to buy) | |
| Coya Therapeutics Inc | Ann Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Coya Therapeutics Inc | Ann Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Nexstar Media Group Inc | Gliha Ann Lee | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2024 | 833 | 8,940 (0%) | 0% | 0 | Common Stock | |
| Nexstar Media Group Inc | Gliha Lee Ann | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2024 | 833 | 1,667 | - | - | Restricted Stock Units | |
| Nexstar Media Group Inc | Ann Lee Gliha | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 158.23 per share. | 20 Dec 2024 | 330 | 8,610 (0%) | 0% | 158.2 | 52,215 | Common Stock |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2024 | 1,250 | 9,091 (0%) | 0% | 0 | Common Stock | |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2024 | 1,250 | 7,841 (0%) | 0% | 0 | Common Stock | |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2024 | 1,250 | 1,250 | - | - | Restricted Stock Units | |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2024 | 1,250 | 1,250 | - | - | Restricted Stock Units | |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 157.63 per share. | 13 Aug 2024 | 984 | 8,107 (0%) | 0% | 157.6 | 155,111 | Common Stock |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 150.56 per share. | 14 Jun 2024 | 938 | 6,400 (0%) | 0% | 150.6 | 141,225 | Common Stock |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 938 | 2,812 | - | - | Restricted Stock Units | |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 938 | 2,812 | - | - | Restricted Stock Units | |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 150.56 per share. | 14 Jun 2024 | 938 | 7,338 (0%) | 0% | 150.6 | 141,225 | Common Stock |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 149.07 per share. | 14 Jun 2024 | 747 | 6,591 (0%) | 0% | 149.1 | 111,359 | Common Stock |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2024 | 656 | 1,313 | - | - | Restricted Stock Units | |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2024 | 656 | 1,313 | - | - | Restricted Stock Units | |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 163.09 per share. | 03 Jun 2024 | 656 | 5,788 (0%) | 0% | 163.1 | 106,987 | Common Stock |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 163.09 per share. | 03 Jun 2024 | 656 | 5,132 (0%) | 0% | 163.1 | 106,987 | Common Stock |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 160.00 per share. | 03 Jun 2024 | 326 | 5,462 (0%) | 0% | 160 | 52,160 | Common Stock |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 7,500 | 7,500 | - | - | Restricted Stock Units | |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 7,500 | 7,500 | - | - | Restricted Stock Units | |
| Prime Medicine Inc | Ann L. Lee | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2024 | 80,416 | 160,832 | - | - | Stock Option (right to buy) | |
| Prime Medicine Inc | Ann L. Lee | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 180,995 | 180,995 | - | - | Stock Option (right to buy) | |
| Coya Therapeutics Inc | Ann Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Nexstar Media Group Inc | Gliha Ann Lee | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Dec 2023 | 2,500 | 18,938 | - | - | Restricted Stock Units | |
| Coya Therapeutics Inc | Ann Lee | Director | Purchase of securities on an exchange or from another person at price $ 3.62 per share. | 22 Aug 2023 | 1,000 | 17,479 | - | 3.6 | 3,620 | Common Stock, par value $0.0001 per share |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 162.09 per share. | 13 Aug 2023 | 1,250 | 4,136 (0%) | 0% | 162.1 | 202,613 | Common Stock |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2023 | 1,250 | 16,438 | - | - | Restricted Stock Units | |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2023 | 1,250 | 17,688 | - | - | Restricted Stock Units | |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 162.09 per share. | 13 Aug 2023 | 1,250 | 5,386 (0%) | 0% | 162.1 | 202,613 | Common Stock |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 160.03 per share. | 13 Aug 2023 | 910 | 4,476 (0%) | 0% | 160.0 | 145,629 | Common Stock |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 3,750 | 15,188 | - | - | Restricted Stock Units | |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 3,750 | 18,938 | - | - | Restricted Stock Units | |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 156.77 per share. | 03 Jun 2023 | 656 | 3,203 (0%) | 0% | 156.8 | 102,841 | Common Stock |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 156.77 per share. | 03 Jun 2023 | 656 | 2,547 (0%) | 0% | 156.8 | 102,841 | Common Stock |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2023 | 656 | 12,094 | - | - | Restricted Stock Units | |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2023 | 656 | 11,438 | - | - | Restricted Stock Units | |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 158.82 per share. | 03 Jun 2023 | 317 | 2,886 (0%) | 0% | 158.8 | 50,345 | Common Stock |
| Prime Medicine Inc | Ann L. Lee | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 180,995 | 180,995 | - | - | Stock Option (right to buy) | |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2022 | 15,000 | 43,000 | - | 0 | Common Stock | |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2022 | 1,250 | 14,000 | - | - | Restricted Stock Units | |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 199.26 per share. | 13 Aug 2022 | 1,250 | 2,195 (0%) | 0% | 199.3 | 249,075 | Common Stock |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 199.26 per share. | 13 Aug 2022 | 1,250 | 1,250 (0%) | 0% | 199.3 | 249,075 | Common Stock |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2022 | 1,250 | 12,750 | - | - | Restricted Stock Units | |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 199.26 per share. | 13 Aug 2022 | 305 | 945 (0%) | 0% | 199.3 | 60,774 | Common Stock |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 199.26 per share. | 13 Aug 2022 | 304 | 1,891 (0%) | 0% | 199.3 | 60,575 | Common Stock |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2022 | 2,625 | 12,625 | - | - | Restricted Stock Units | |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2022 | 2,625 | 15,250 | - | - | Restricted Stock Units | |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 81,250 | 473,594 | - | - | Stock Option (Right to Buy) | |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 56,744 | 366,344 | - | - | Stock Option (Right to Buy) | |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 43,750 | 124,006 | - | 0 | Common Stock | |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 26,000 | 392,344 | - | - | Stock Option (Right to Buy) | |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 23,256 | 51,256 | - | 0 | Common Stock | |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 14,000 | 65,256 | - | 0 | Common Stock | |
| Coya Therapeutics Inc | Ann Lee | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 03 Jan 2022 | 10,000 | 10,000 | - | - | Common Stock, par value $0.0001 per share | |
| Coya Therapeutics Inc | Ann Lee | Director | 03 Jan 2022 | 6,479 | 16,479 | - | 4 | 25,916 | Common Stock, par value $0.0001 per share | |
| Coya Therapeutics Inc | Ann Lee | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 03 Jan 2022 | 5,000 | 9,479 | - | - | Warrant to Purchase Common Stock | |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 22.26 per share. | 12 Nov 2021 | 14,266 | 2,294,876 | - | 22.3 | 317,628 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 21.92 per share. | 12 Nov 2021 | 6,122 | 2,288,254 | - | 21.9 | 134,167 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 23.18 per share. | 12 Nov 2021 | 500 | 2,294,376 | - | 23.2 | 11,588 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 21.76 per share. | 12 Nov 2021 | 100 | 2,288,154 | - | 21.8 | 2,176 | Common Stock |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2021 | 5,000 | 10,000 | - | - | Restricted Stock Units | |
| Nexstar Media Group Inc | Lee Ann Gliha | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2021 | 5,000 | 5,000 | - | - | Restricted Stock Units | |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 22.75 per share. | 10 May 2021 | 150,000 | 2,309,142 | - | 22.8 | 3,412,500 | Common Stock |
| Summit Materials Inc - Ord... | Anne Lee Benedict | See Remarks | 18 Mar 2021 | 53,172 | 0 | - | - | LP Units of Summit Materials Holdings L.P. | ||
| Summit Materials Inc - Ord... | Anne Lee Benedict | See Remarks | 18 Mar 2021 | 53,172 | 73,585 (0%) | 0% | - | Class A Common Stock | ||
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 16 Mar 2021 | 3,025 | 2,459,142 | - | 30.0 | 90,751 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 38.46 per share. | 01 Mar 2021 | 6,359 | 2,465,326 | - | 38.5 | 244,572 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 39.18 per share. | 01 Mar 2021 | 3,159 | 2,462,167 | - | 39.2 | 123,758 | Common Stock |
| Summit Materials Inc - Ord... | Anne Lee Benedict | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 5,780 | 5,780 | - | - | Restricted Stock Units | |
| Summit Materials Inc - Ord... | Anne Lee Benedict | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 5,780 | 20,146 (0%) | 0% | - | Class A Common Stock | |
| Summit Materials Inc - Ord... | Anne Lee Benedict | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 4,007 | 8,012 | - | - | Restricted Stock Units | |
| Summit Materials Inc - Ord... | Anne Lee Benedict | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 4,007 | 24,153 (0%) | 0% | - | Class A Common Stock | |
| Summit Materials Inc - Ord... | Anne Lee Benedict | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.71 per share. | 28 Feb 2021 | 3,740 | 20,413 (0%) | 0% | 27.7 | 103,635 | Class A Common Stock |
| Summit Materials Inc - Ord... | Anne Lee Benedict | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 2,752 | 14,366 (0%) | 0% | - | Class A Common Stock | |
| Summit Materials Inc - Ord... | Anne Lee Benedict | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 2,752 | 0 | - | - | Restricted Stock Units | |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 41.75 per share. | 19 Feb 2021 | 7,541 | 2,481,590 | - | 41.8 | 314,868 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 42.84 per share. | 19 Feb 2021 | 4,506 | 2,475,884 | - | 42.8 | 193,034 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 39.59 per share. | 19 Feb 2021 | 1,907 | 2,472,485 | - | 39.6 | 75,498 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 38.83 per share. | 19 Feb 2021 | 1,492 | 2,474,392 | - | 38.8 | 57,931 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 41.54 per share. | 19 Feb 2021 | 1,200 | 2,480,390 | - | 41.5 | 49,846 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 40.56 per share. | 19 Feb 2021 | 800 | 2,471,685 | - | 40.6 | 32,448 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 41.50 per share. | 18 Feb 2021 | 1,300 | 2,489,131 | - | 41.5 | 53,950 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 40.44 per share. | 18 Feb 2021 | 1,100 | 2,490,431 | - | 40.4 | 44,484 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 39.20 per share. | 18 Feb 2021 | 300 | 2,491,531 | - | 39.2 | 11,760 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 41.82 per share. | 16 Feb 2021 | 2,850 | 2,494,317 | - | 41.8 | 119,175 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 41.28 per share. | 16 Feb 2021 | 1,386 | 2,491,831 | - | 41.3 | 57,215 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 38.63 per share. | 16 Feb 2021 | 500 | 2,493,617 | - | 38.6 | 19,313 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 39.85 per share. | 16 Feb 2021 | 400 | 2,493,217 | - | 39.9 | 15,940 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 42.79 per share. | 16 Feb 2021 | 200 | 2,494,117 | - | 42.8 | 8,558 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Jan 2021 | 60,394 | 0 | - | 0 | Common Stock | |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Jan 2021 | 60,394 | 60,394 | - | 0 | Common Stock | |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2021 | 52,000 | 52,000 | - | - | Stock Option (Right to Buy) | |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2021 | 28,000 | 28,000 | - | 0 | Common Stock | |
| Summit Materials Inc - Ord... | Anne Lee Benedict | See Remarks | 02 Nov 2020 | 8,250 | 20,114 (0%) | 0% | - | Class A Common Stock | ||
| Summit Materials Inc - Ord... | Anne Lee Benedict | See Remarks | 02 Nov 2020 | 8,250 | 53,172 | - | - | LP Units of Summit Materials Holdings L.P. | ||
| Summit Materials Inc - Ord... | Anne Lee Benedict | See Remarks | Sale of securities on an exchange or to another person at price $ 18.48 per share. | 02 Nov 2020 | 7,450 | 11,864 (0%) | 0% | 18.5 | 137,639 | Class A Common Stock |
| Summit Materials Inc - Ord... | Anne Lee Benedict | See Remarks | Sale of securities on an exchange or to another person at price $ 18.49 per share. | 02 Nov 2020 | 800 | 19,314 (0%) | 0% | 18.5 | 14,792 | Class A Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | 03 Aug 2020 | 3,631,293 | 0 | - | - | Series A-3 Convertible Preferred Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges